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Arsenic (As), a ubiquitous environmental con­
taminant, presents significant human health 
risks: Chronic exposure is associated with the 
development of cancer in the bladder, liver, 
kidney, and lungs (Chen et al. 1992). Regions 
with a high geogenic As background show an 
increased risk for elevated exposure by con­
sumption of drinking water and diet. An addi­
tional exposure scenario in urban areas near 
smelting and mining activities is the ingestion 
of contaminated soil and dust by children, 
who display typical hand­to­mouth behavior. 
Although inorganic As (iAs) may be the pre­
dominant form in contaminated soils, As spe­
ciation changes during gastro  intestinal transit 
are not well charac  terized. The gut represents 
a highly reducing environment and harbors 
a complex microbial community, which may 
contribute to the pre  systemic biotransfor­
mation of ingested As (systemic metabolism 
being defined as all metabolic reactions carried 
out by human cells). Presystemic As specia­
tion analysis must therefore be considered an 
essential part of the risk evaluation process, 
especially with respect to toxicity, which is 
speciation dependent. In short, methylated 
trivalent species—monomethylarsonous acid 
(MMAIII), dimethylarsinous acid (DMAIII), 
and arsenous acid (iAsIII)—are two orders 
of magnitude more cytotoxic than is As acid 
(iAsV) (Naranmandura et al. 2007a). The 
methylated penta  valent species—monomethyl­
arsonic acid (MMAV) and dimethylarsinic 
acid (DMAV)—present a 10­fold lower toxic­
ity than iAsV, whereas trimethyl    arsine oxide 
(TMAO) is essentially non  toxic (Hirano 
et al. 2004).
In the human body, iAs is sequentially 
methylated and predominately excreted as 
DMAV in urine. This methylation process was 
originally considered a detoxification process, 
but the formation of reactive intermediates 
(MMAIII and DMAIII) has forced researchers 
to reconsider methylation as an activation pro­
cess (Styblo et al. 2002). In addition, a recent 
study on human urine analysis after iAs expo­
sure revealed new sulfur­containing methylated 
As metabo  lites, monomethyl  mono  thio  arsonic 
acid (MMMTAV) and dimethyl  mono  thio­
arsinic acid (DMMTAV) (Naranmandura 
et al. 2007b; Raml et al. 2007), for which the 
mechanism of formation and toxicological 
profile are not yet fully charac  terized. Given 
the toxicological importance of As speciation 
changes, it is clear that a complete risk charac­
terization after As exposure must include 
the possibility of presystemic metabolism by 
the microbe­rich environment of the gastro­
intestinal tract.
The colon harbors a vast (1014 bacterial 
cells) and incredibly diverse (> 1,000 species) 
microbial community, which has the abil­
ity to metabolize xeno  biotics far more exten­
sively than any other part of the body (Sousa 
et al. 2008). Thus far, the presystemic bio­
t  ransforma  tion of As was primarily studied 
with gut micro  biota from animal models.   
Rowland and Davies (1981) reported the 
reduction of iAsV to iAsIII by rat cecal bac­
teria as well as limited formation of MMA 
and DMA. In another study with rats orally 
exposed to DMAV Chen et al. (1996) 
detected demethylated (iAsV, MMAV) and 
methylated (TMAO) urinary metabolites. 
Finally, the thiolation of methylated As oxides 
(DMAV, TMAO) in the cecal contents of a 
mouse (Kubachka et al. 2009a, 2009b) and 
the observed thiolation through in vivo experi­
ments (Kuroda et al. 2004; Naranmandura 
et al. 2007b) have been reported. 
Presystemic As metabolism in the human 
body has been less investigated (Hirner 
et al. 2004). Nevertheless, Michalke et al. 
(2008) reported that human gut microbes 
actively volatilize bismuth and other metal­
loids, including As, through methyla  tion and 
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Ba c k g r o u n d: Speciation analysis is essential when evaluating risks from arsenic (As) exposure. 
In an oral exposure scenario, the importance of presystemic metabolism by gut microorganisms 
has been evidenced with in vivo animal models and in vitro experiments with animal microbiota. 
However, it is unclear whether human microbiota display similar As metabolism, especially when 
present in a contaminated matrix.
oBjectives: We evaluated the metabolic potency of in vitro cultured human colon microbiota 
toward inorganic As (iAs) and As­contaminated soils. 
Me t h o d s : A colon microbial community was cultured in a dynamic model of the human gut. These 
colon microbiota were incubated with iAs and with As­contaminated urban soils. We determined 
As speciation analysis using high­performance liquid chromatography coupled with inductively 
coupled plasma mass spectrometry. 
re s u l t s: We found a high degree of methylation for colon digests both of iAs (10 µg 
methylarsenical/g biomass/hr) and of As­contaminated soils (up to 28 µg/g biomass/hr). Besides 
the formation of monomethylarsonic acid (MMAV), we detected the highly toxic mono  methyl­
arsonous acid (MMAIII). Moreover, this is the first description of microbial thiolation leading to 
monomethyl  monothioarsonic acid (MMMTAV). MMMTAV, the toxicokinetic properties of which 
are not well known, was in many cases a major metabolite. 
co n c l u s i o n s: Presystemic As metabolism is a significant process in the human body. Toxicokinetic 
studies aiming to completely elucidate the As metabolic pathway would therefore benefit from 
incorporating the metabolic potency of human gut microbiota. This will result in more accurate risk 
characterization associated with As exposures.
key w o r d s : arsenic species, bacteria, colon, gastrointestinal, metalloid, microflora, presystemic 
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hydrogenation. Moreover, Meyer et al. (2008) 
postulated that gut methanogens play a crucial 
role in metalloid volatilization, thereby exert­
ing toxic effects to the human body—not only 
by direct interaction with the host but also 
by disturbing the endogenous gut microbiota 
composition and metabolism. Finally, a thor­
ough in vitro exploration with the Simulator 
of the Human Intestinal Microbial Ecosystem 
(SHIME), a dynamic human gastrointestinal 
simulator, revealed a high microbial meta­
bolic potency toward metal(loid)s (Diaz­Bone 
and Van de Wiele 2009). This was demon­
strated by the finding of significant volatiliza­
tion of As, selenium, bismuth, tellurium (Te), 
and antimony; the formation of highly toxic 
AsH3 (arsine) and (CH3)2Te (dimethyl tellu­
ride); and the discovery of two new As–sulfur 
metabolites. 
These data indicate the need for more 
studies with human gut microorganisms, 
which can confirm the presystemic metabo­
lism as observed with animal gut micro  biota. 
Therefore, in the present study we investigated 
the metabolic potency of human gut micro­
organisms toward iAs and As from contami­
nated urban soils, assessing the importance 
of presystemic As biotransformation upon an 
oral exposure scenario and the actual specia­
tion of As that enters the bloodstream upon 
gastro  intestinal digestion.
Materials and Methods 
Chemicals and media. We used degassed, 
ultrapure 18 mΩ water (DDI; Millipore, 
Bedford, MA, USA) to prepare the chromato­
graphic mobile phase and the standard stock 
solutions. American Chemical Society–grade 
ammonium nitrate and ammonium dihydro­
gen phosphate (Fisher Scientific, Pittsburgh, 
PA, USA) and technical­grade EDTA, tet­
rasodium salt dehydrate (Fisher Scientific, 
Fair Lawn, NJ, USA) were used in the chro­
matographic mobile phase. We obtained stock 
solutions of iAs (AsIII and AsV) from Spex 
Industries (Metuchen, NJ, USA) and certi­
fied stock solutions of MMAV and DMAV 
from Chem Service (West Chester, PA). W.R. 
Cullen (Department of Chemistry, University 
of British Columbia, Vancouver, BC, Canada) 
provided tetramethyl­cyclo­tetraarsaoxane 
[cyclo­(CH3AsO)4] crystals that were syn­
thesized and characterized as described else­
where (Cullen et al. 1989); these crystals 
were stored at –21°C and were hydrolyzed by 
degassed, deionized water at the time of analy­
sis to obtain a stock solution of a MMAIII and 
MMAV mixture (Cullen et al. 1989). We pur­
chased sodium arsenate (Na2HAsO4·7H2O), 
methionine, methyl  cobalamine, and gluta­
thione from Sigma­Aldrich (St. Louis, MO, 
USA). Arsenate stock solutions were prepared 
in deionized water at 4,500 mg As/L and 
45 mg As/L. 
Soils. The U.S. Environmental Protection 
Agency kindly provided four As­contaminated 
soils that originated from urban areas around 
former smelting sites. We sieved all soils at 
250 µm before in vitro gastrointestinal incu­
bation; this sieving reflects the size of particles 
that most likely sticks to the hands of exposed 
humans (Kelly et al. 2002). Soil specifications 
are reported in Table 1.
Production and characterization of colon 
micro  biota for SHIME. The in vitro colon 
microbial community used in this study 
was cultured and maintained in a modified 
SHIME, which consisted of four compart­
ments simulating the stomach, small intes­
tine, and both proximal and distal colon. 
A detailed description of the SHIME, the 
carbohydrate­based medium, and the in vitro 
colon microbiota has been described previ­
ously (Van de Wiele et al. 2004). Briefly, 
fecal microbiota previously obtained from a 
29­year­old male volunteer (who had no his­
tory of anti  biotic treatment in the 6 months 
before the study) were inoculated in the dif­
ferent colon compartments. The SHIME 
reactor was fed carbohydrate­based medium 
three times per day to provide digested nutri­
tion for the colon microbiota. After 3 weeks 
of adaptation, a stable microbial community 
was obtained in the respective colon com­
partments. We found microbial fermentation 
activity of the distal colon (short­chain fatty 
acid production and ammonium production) 
and community composition to be consistent 
with that of previous SHIME runs and the 
in vivo situation (Molly et al. 1994; Van de 
Wiele et al. 2004) [see Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901794)]. 
Noncontinuous incubation   studies. 
Metabolic potency of fecal microbial 
inocu  lum. The first experiment constituted 
a screening phase to test whether the fecal 
microbial community from human ori­
gin actively metabolized As. The microbial 
community was isolated from a fecal sample 
as previously described by Molly et al. (1994). 
Thirty milliliters of microbial fecal suspension 
was sampled, placed in 60­mL serum bot­
tles, and incubated with NaH2AsO4·7H2O 
(iAsV; 90 mg iAsV/L), similar to the method 
of Herbel et al. (2002). Serum bottles were 
capped with butyl rubber stoppers that are 
impervious to O2 and subsequently made 
anaerobic by flushing with N2 gas for 
30 min. Samples were then incubated at 
37°C on a rotary shaker (150 rpm) for 48 hr. 
We compared the effect of specific methyl 
group donors toward microbial As methy­
lation by comparing methionine­amended 
(5 mmol/L) and methyl  cobalamin­amended 
(5 mmol/L) samples with control samples 
(incubation of the sample in the presence of 
heat­sterilized fecal microbiota). The effect 
of glutathione as a reducing agent was eval­
uated by comparing glutathione­amended 
samples (10 mmol/L) with control samples. 
Duplicate incubations were performed on 
two different days to evaluate the reproduc­
ibility. A scheme of the experimental setup is 
presented in Supplemental Material, Figure 1 
(doi:10.1289/ehp.0901794).
Metabolic potency of colon microbiota 
toward As from contaminated soils. The objec­
tive of the second experiment was to screen for 
microbial speciation changes of iAsV at more 
relevant concentrations (i.e., 50–500 µg/L) 
by mimicking conditions of oral exposure 
to environmental samples. In addition, four 
As­contaminated soil samples (one slag soil 
and three from urban sites) were subjected to a 
gastro  intestinal digestion procedure. To better 
mimic in vivo conditions, all gastrointestinal 
stages—gastric, small intestine, and colon—
were simulated. We combined the in vitro 
gastro  intestinal method (IVG) from Ohio State 
University with the SHIME to subsequently 
simulate stomach and small intestine (IVG) and 
colon (SHIME) conditions, respectively. The 
Table 1. Characteristics and elemental composition of the four As-contaminated soils.
Characteristic Soil 1 Soil 2 Soil 3 Soil 4 (slag)
Organic carbon (%) 5.7 4.0 3.1 2.2
pHa 6.1 6.3 5.0 7.2
Electric conductivity (dS/m) 0.3 0.5 0.9 0.5
Fe (mg/kg) 14,800 15,250 12,100 202,000
Mn (mg/kg) 429 525 207 1,640
Reactive Feb 3,489 3,592 1,634 18,759
Percent bioaccessibility with IVGc 58.5 62.4 47.7 1.0
Toxic trace element content (mg/kg)
As 990 829 379 837
Cadmium  9.7 5.5 1.5 28.9
Chromium  32.0 31.4 28.7 187
Copper  51.9 60.1 22.2 1,520
Molybdenum 2.1 2.4 1.5 73.9
Nickel 12.5 10.9 9.3 10.4
Lead  885 602 172 8,702
Selenium 330 430 127 294
Zinc 562 803 151 12,500
aSoil pH was determined in a 1:10 (wt/vol) aqueous soil slurry. bIron dissolved by acid ammonium oxalate extraction. 
cData from Whitacre (2009). Van de Wiele et al.
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IVG method was previously validated against 
in vivo data for As bioaccessibility (Rodriguez 
and Basta 1999), whereas the SHIME has been 
validated against in vivo data for microbial 
community composition and metabolic activity 
toward drugs and phyto  estrogens (Molly et al. 
1994; Possemiers et al. 2006).
Soils were incubated in the gastric and 
intestine solution (30 mL) of the IVG pro­
tocol at a liquid­to­soil (L/S) ratio of 150 
(Rodriguez and Basta 1999). These intesti­
nal digests from the IVG protocol were sub­
jected to colon conditions by adding 30 mL 
of the colon suspension sampled from the dis­
tal colon compartment of the SHIME reac­
tor, resulting in an L/S ratio of 300 for the 
soil digests. The vessels containing the colon 
digests were capped with butyl rubber stop­
pers and subsequently flushed with N2 for 
30 min to obtain anaerobic conditions and 
incubated on a shaker at 150 rpm at 37°C for 
18 hr. See Supplemental Material, Figure 1 
(doi:10.1289/ehp.0901794) for a schematic of 
the experimental setup.
Sample treatment. To preserve the spe­
ciation of As in the colon digests, all samples 
were flash frozen with liquid nitrogen upon 
incubation and subsequently stored at –80°C. 
Before analysis with high­performance liquid 
chromatography (HPLC) coupled with induc­
tively coupled plasma (ICP) mass spectrom­
etry (MS), samples were thawed and diluted 
appropriately with 20 mmol/L (NH4)2CO3 at 
pH 9.0 to minimize sulfur–oxygen exchange 
while awaiting analysis (Conklin et al. 2008). 
Upon complete thawing, the sample was vor­
texed and centrifuged for 10 min at 10,400 rel­
ative centrifugal force with an Eppendorf 
5810R centrifuge (Brinkman Instruments, 
Westburg, NY, USA) to separate soluble As 
species from soil­bound As. The supernatant 
was filtered through a Millex­LCR 0.45 µm fil­
ter (Millipore) with a Luer­Lok 10­mL syringe 
(BD, Franklin Lakes, NJ, USA). Finally, 
filtrates were diluted with the mobile phase 
and injected into the HPLC. The sum of the 
As species in the filtrate observed chromato­
graphically was considered the bioaccessible 
fraction. We measured total As concentration 
in the digest filtrates using ICP optical emis­
sion spectroscopy (ICP­OES). This allowed us 
to calculate chromatographic recovery, which 
quantifies the extent to which the sum of the 
chromatographic As species comprises the total 
amount of As in the digest filtrates. 
As speciation analysis by HPLC/ICP-MS. 
Sample supernatants were analyzed with HPLC 
(Agilent 1100) and ICP­MS (Agilent 7500ce; 
Agilent, Palo Alto, CA, USA) for As specific 
detection at m/z 75. Separation of As oxides 
was performed on a PRP­X100 HPLC column 
(250 mm × 4.1 mm, 5 µm). The mobile phase 
was a solution of NH4NO3 (10 mmol/L), 
NH4H2PO4 (10 mmol/L), and EDTA 
(500 mg/L) at pH 4.57 in distilled water (sepa­
ration 1). The flow rate was 1.0 mL/min, and 
the sample injection volume was 100 µL. The 
retention times of the separated compounds 
were 3.6 min for AsIII, 4.2 min for DMAV, 
5.5 min for MMAIII, 7.1 min for MMAV, 
and 8.9 min for AsV, similar to those previ­
ously reported by Yathavakilla et al. (2008). 
We used this separation for quantification of 
the As species of interest. Arsenic sulfides were 
identified by retention­time matching between 
samples and fortified samples. Using chromato­
graphic separation 1, monothioarsonic acid 
eluted at 15 min, whereas MMMTAV eluted 
at 18.6 min. See the Supplemental Material 
(doi:10.1289/ehp.0901794) for details on syn­
thesis, chromatographic confirmation of these 
As sulfides, and sample analysis. 
A second chromato  graphy [separation 2; 
see Supplemental Material (doi:10.1289/
ehp.0901794)] was used for ICP­MS and 
electrospray ionization (ESI)­MS detection, 
because the mobile phase of separation 1 was 
not compatible with ESI­MS detection. 
Results
In the first experiment, we assessed the meta­
bolic potency of the human fecal microbial 
inoculum toward high levels of iAsV (90 mg/L). 
iAsV was efficiently (> 94%) reduced to iAsIII 
after the 48­hr incubation with both active 
and sterilized fecal microbiota (Table 2), prob­
ably because of the highly reducing conditions 
(redox potential was –180 mV). Incubation 
with sterilized fecal microbiota did not lead to 
thiolated or methylated arsenicals. In contrast, 
incubation of iAsV with active fecal microbiota 
resulted in the production of mono  thio  arsonic 
acid (mTA; mean ± SD) in non  amended 
(2.2 ± 3.1 mg/L) and methionine­amended 
(0.8 ± 1.1 mg/L) samples. Interestingly, we 
observed methylation only in the presence of 
methyl  cobalamin. Addition of the methyl­
cobalamin displayed a significant methylation 
of iAs (18%), with MMAV (13.0 ± 1.4 mg/L) 
being  more  dominant  than  MMAIII 
(2.6 ± 1.4 mg/L). The addition of both methyl­
cobalamin and glutathione as a reducing 
agent increased the methylation to 28%, with 
MMAIII (10.5 ± 5.4 mg/L) becoming equally 
as important as MMAV (11.3 ± 5.6 mg/L).
These preliminary data convinced us 
that the selected microbial community had 
the potency to actively metabolize iAsV. We 
therefore inoculated the SHIME reactor with 
this fecal microbial inoculum; after 3 weeks 
of adaptation, a stable microbial community 
was obtained in the proximal and distal colon 
compartments. We regularly sampled the 
distal colon compartment to perform colon 
incubations on iAsV and As­contaminated soil 
samples that had already gone through a gas­
tric and intestinal digestion. Characterization 
of the colon digests consisted of determin­
ing As bio  accessibility and As speciation. The 
bioaccessibility determination was based on 
the sum of all chromatographically detected 
(HPLC/ICP­MS) As species in the filtrates 
(0.45 µm) of the colon digests; therefore, the 
chromatographic recovery was calculated first. 
The sum of the concentrations of chromato­
graphically detected As species in the colon 
Table 2. Influence of cofactors toward microbial metabolism during in vitro fecal incubation of iAsV at 
90 mg/L.
Microbiota AsV AsIII MMAV MMAIII mTA Recovery (%)
Active microbiota
No cofactor 1.7 ± 2.3 97.6 ± 2.5 ND ND 2.2 ± 3.1 113
Me-B12 2.6 65.3 13.0 ± 1.4 2.6 ± 1.4 ND 93
Meth 1.7 ± 2.3 103.4 ± 3.1 ND ND 0.8 ± 1.1 118
GSH ND 93.2 ± 18.8 ND ND ND 104
Me-B12/Meth/GSH 2.0 ± 1.2 53.6 ± 9.7 11.3 ± 5.6 10.5 ± 5.4 ND 86
Sterilized microbiotaa
No cofactor 5.6  87.6 ND ND ND 104
Me-B12 4.6 72.7 ND ND ND 86
Meth 4.6 86.8 ND ND ND 102
GSH ND 84.6 ND ND ND 94
Me-B12/Meth/GSH 3.5 83.7 ND ND ND 97
Abbreviations: GSH, glutathione; Me-B12, methylcobalamin; Meth, methionine; ND, not detected. Values are mean ± SD 
(mg/L) from duplicate incubation experiments 
aIncubation tests with sterilized microbiota were performed once, so no SD is available. 
Table 3. Percentage bioaccessibility of As and 
biomass-specific production rate of methyl-
ated arsenicals by colon microorganisms after 
in vitro colon digestion of iAsV (225 μg/L) and 
As-contaminated soils.
Sample
Percent 
bioaccessibilitya
Methylation rate 
(μg/hr/g biomass)b
Na2HAsO4·7H2O 76 ± 14.3 10.0 ± 4.0
Soil 1 24 ± 4.3 10.0 ± 1.8
Soil 2 44 ± 3.9 4.2 ± 1.6
Soil 3 36 ± 1.5 28.9 ± 3.4
Soil 4 0.3 ± 0.1 ND
ND, not detected. Values are mean ± SD of three 
  experiments. 
aCalculated by dividing the sum of detected As species 
(iAsV, iAsIII, mTA, MMAV, MMAIII, and MMMTAV) in the 
colon digest filtrate by the total amount of As that was 
incubated under colon conditions. bCalculated by divid-
ing the sum of methylated arsenicals (MMAV, MMAIII, 
and MMMTAV) in the colon digest filtrate by the initial 
biomass concentration and the incubation time. Arsenic metabolism by human gut microbiota
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filtrates was divided by the total As concen­
tration in the colon filtrates, as measured by 
ICP­OES. The chromatographic recoveries 
for all colon digests, except for that of soil 4, 
were satisfactorily high: 93 ± 7% (mean ± SD) 
on average [the recovery of the soil 4 digest 
excluded; see Supplemental Material, Table 2 
(doi:10.1289/ehp.0901794)]. Hence, most 
As species present in these digest super­
natants could be detected with the HPLC/
ICP­MS protocol. Bioaccessibility calcula­
tions for these digests displayed the highest 
value (75.5%) for the iAsV­incubated colon 
digest, whereas colon incubation of the con­
taminated soils resulted in As bioaccessibility 
values of 24% (soil 1), 44% (soil 2), and 36% 
(soil 3) (Table 3). In sharp contrast, As bio­
accessibility in the colon digest of soil 4 was 
only 0.3%. Even when taking into account 
the low chromatographic recovery of 15%, 
we obtained a low As bioaccessibility of 2.4%, 
which is still an order of magnitude lower 
than the bioaccessibility values for the other 
soil digests. Overall, colon bioaccessibility val­
ues (Table 3) for the four soils were consis­
tently lower than the corresponding intestinal 
bioaccessibility values (Table 1) obtained with 
the IVG method.
The most important part of this study 
consisted of the As speciation analysis of the 
colon digests after the gastrointestinal incu­
bation of iAsV and the four contaminated 
soils. The original analytical protocol was 
optimized to detect the presence of iAsIII, 
iAsV, MMAIII, and MMAV. We detected an 
additional As species, MMMTAV, in many 
of the colon digests. We initially identified 
MMMTAV using a combination of reten­
tion­time matching and by fortifying the 
sample with the suspected standard using 
separation 1 with ICP­MS detection, but we 
used a second chromato  graphy (separation 2) 
for ICP­MS and ESI­MS detection. Figure 1 
shows HPLC/ICP­MS mass chromatograms 
of m/z 75 (75As) and HPLC/ESI­MS mass 
chromatograms of m/z 155 ([M­H]–) for an 
MMMTAV standard and a SHIME extract 
using separation 2. The retention times of the 
MMMTAV in the standard and MMMTAV 
in the sample were slightly offset because the 
matrix of the soil extract caused the decreased 
retention of MMMTAV on the C18 column. 
Tandem MS (MS/MS) of m/z 155 yielded a 
product ion of m/z 137 (loss of H2O) and, 
to a lesser extent, a product ion of m/z 121 
(due to CH2AsO2
–) and m/z 140 (loss of 
CH3). The molecular mass of 155 and cor­
responding fragments were consistent with 
other reports for MMMTAV (Yathavakilla 
et al. 2008).
We detected significant As methylation 
upon colon incubation of 225 µg iAsV/L 
(Figure 2). The sum of the concentrations of 
MMAV (31.0 µg/L), MMAIII (4.5 µg/L), and 
MMMTAV (43.7 µg/L) exceeded that of iAsV 
(39.0 µg/L) and iAsIII (34.8 µg/L). In contrast, 
iAs species were predominantly present in 
colon digests of soils 1, 2, and 3, whereas they 
were the only As species in the colon digest 
of slag soil 4 (Figure 2). The colon digest of 
soil 1 displayed a methylation percentage of 
4.7% with MMAV (17 µg/L) and MMMTAV 
Figure 1. Identification of MMMTAV by HPLC/ESI-MS/MS and HPLC/ICP-MS (left) [using separation 2; see 
Supplemental Material (doi:10.1289/ehp.0901794)]. The gray and black traces in chromatograms represent 
analysis of a soil extract and MMMTAV standard, respectively. Right: MS/MS spectra of m/z 155 within 
each MS spectra. 
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Figure 2. Concentration (mean ± SD) of chromatographically detected As species in colon digests of iAsV 
(225 μg/L) and of As-contaminated soils 1–4 (n = 3). Note the different scales for the As concentrations 
(y‑axis) for iAsV and contaminated soils. 
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(23 µg/L) as detected methylarsenicals. The 
methylation percentage for colon digests of 
soil 2 (22.8%) and soil 3 (21.2%) was higher, 
with soil 2 displaying MMAV (111 µg/L), 
MMAIII (9 µg/L), and MMMTAV (158 µg/L) 
and soil 3 displaying only MMAV (28 µg/L) 
and MMMTAV (68 µg/L). Finally, no meth­
ylated As species were detected in the colon 
digests of slag soil 4.
Summarizing the in vitro As speciation 
changes by human gut microorganisms, we 
calculated the specific production rates of 
methylated arsenicals by taking into account 
the initial microbial biomass and As con­
centrations. We obtained a methylation rate 
of 10 µg methylarsenicals/g biomass/hr for 
the colon digest of iAsV (Table 3). Although 
no methylarsenicals were detected in colon 
digests of the slag soil 4, the presence of the 
other soil matrices did not necessarily lower 
the above­mentioned methylation rate. We 
obtained methylation rates of 4, 29, and 
10 µg/g/hr for colon digests of soils 1, 2, 
and 3, respectively (Table 3).
Discussion
The present study demonstrates that human 
colon micro  organisms have the potency to 
actively metabolize As into methylated 
arsenicals and thioarsenicals, which indicates 
that presystemic As metabolism may not 
be neglected when assessing risks from oral 
As exposure. We observed this upon colon 
incubation of both iAs and As­contaminated 
soils. These findings parallel those from 
studies with animal gut microbiota (Hall 
et al. 1997; Rowland and Davies 1981) and 
suggest the existence of a presystemic As 
metabolism in the human body. The most 
important result was the detection of signif­
icant levels of MMMTAV in colon digests 
of both iAsV (25% of bioaccessible As) and 
of As­contaminated soils (up to 20% of bio­
accessible As). To our knowledge, this is the 
first time that MMMTAV production from 
iAsV by human colon microbiota has been 
described. MMMTAV production from this 
source resembles the methylation and thiola­
tion of DMAV into trimethylarsine sulfide 
by mouse cecal microbiota (Kubachka et al. 
2009a) and the production of methylated 
thio  arsenicals from DMAV by rat intestinal 
microbiota (Kuroda et al. 2004; Yoshida et al. 
2001). Yet, mammalian cells also have the 
ability to form methylated thioarsenicals. 
Kuroda et al. (2004) described rapid detection 
(5 min) of DMMTAV and dimethyldithioars­
inic acid (DMDTAV) after injection of of rats 
with DMAIII, and Naranmandura and Suzuki 
(2008) reported that DMAIII was converted to 
DMDTAV by human red blood cells. 
The finding of presystemic MMMTAV 
formation by human gut micro  organisms 
raises questions about its toxicological 
importance. Although the absorption kinetics 
of MMMTAV and other thiolated arsenicals 
across the epithelium are unknown, there is 
evidence that some methylated thio  arsenicals 
elicit a higher toxicity than iAsV because of 
their more efficient absorption by mam­
malian cells (Naranmandura et al. 2007a). 
Preliminary cytotoxicity (Naranmandura 
et al. 2007a; Yoshida et al. 2003) and 
genotoxicity (Kuroda et al. 2004) data for 
DMMTAV show levels of toxicity similar to 
those of trivalent As species. Our observa­
tions in the present study emphasize the need 
to investigate the behavior of MMMTAV in 
the gut lumen and the absorption rate across 
the intestinal epithelium. In addition, the 
mechanism behind the microbial production 
pathway needs to be elucidated. Interestingly, 
MMMTAV levels in the colon digests cor­
related with those of MMAV (R2 = 0.76), 
whereas the correlation with levels of MMAIII 
was much lower (R2 = 0.42). This seems to 
indicate that MMMTAV in the colon digests 
arises from the thiolation of MMAV, which 
would correspond with earlier observations 
describing the interconversion between oxide 
and sulfide forms of MMAV, DMAV, and 
TMAO (Conklin et al. 2008). The sulfide 
source may originate from microbial sulfate 
reduction to hydrogen sulfide, which is a 
common process in the colon environment 
(Deplancke et al. 2000), and can trigger the 
formation of thioarseno  sugars upon the 
incubation of arsenosugars with mouse cecal 
contents (Conklin et al. 2006). The role of 
sulfate­reducing micro  organisms in the pre­
systemic production pathway of MMMTAV 
must therefore be studied further.
The significant formation of MMAV and 
MMAIII after incubation of iAsV with colon 
micro  organisms was not unexpected. Arsenic 
methylation by rodent gut microbes (Hall 
et al. 1997; Rowland and Davies 1981) and 
human gut microbes (Diaz­Bone and Van 
de Wiele 2009; Meyer et al. 2008) has been 
described previously. Taking into account the 
initial biomass concentration, we observed 
specific methylation rates of 10 µg methyl­
arsenicals/hr/g biomass. This roughly corre­
sponds to 130 pmol/hr/mg biomass, which 
is > 16 pmol/hr/mg obtained with rat cecal 
microbiota (Hall et al. 1997). Interestingly, 
the presence of a soil matrix did not neces­
sarily result in lower As methylation rates, yet 
soil­dependent parameters may have affected 
the methylation rate. First, comparison of the 
mineralogy from soils 1, 2, and 3 with that of 
slag (soil 4) showed an important difference in 
reactive iron oxide content (Table 1), which 
is highly efficient in sorbing As (Beak et al. 
2006). The reactive iron oxide content in slag 
soil 4 was particularly high (18,759 µg/kg; 
Table 1), presumably leading to much lower 
As availability to colon microorganisms 
(0.3% bio  accessibility) and thus also limiting 
methyla  tion. This observation may confirm 
earlier observations of slag soil mineralogy sig­
nificantly decreasing As bioavailability (Davis 
et al. 1996). A second element in the soil­
dependent As methylation may be the differ­
ence in toxic elements. Compared with the 
first three soils, slag (soil 4) contained high 
amounts of cadmium, chromium, copper, 
molybdenum, lead, and zinc (Table 1), which 
may be toxic to intestinal micro  organisms. 
Our finding of a 70% lower fermentation 
activity in soil 4 colon digests versus colon 
digests of the other soils (data not shown) may 
support the assumption of slag­soil–induced 
toxicity. The actual relationship between gut 
microbial As metabolism and soil characteris­
tics therefore needs further study.
A final aspect of our study concerns the 
metabolic potency of fecal microbes toward 
high levels of iAsV (90 mg iAsV/L) and the 
influence of cofactors. Non  amended colon 
digests of iAsV resulted in the efficient reduc­
tion to iAsIII and the production of mTA. 
Similar to the finding of MMMTAV, the for­
mation of mTA may result from an oxygen­
for­sulfur exchange in iAsV because of the 
availability of sulfide, originating from the 
above­mentioned microbial sulfate reduction. 
The absence of mTA in glutathione­amended 
samples may be explained by the complete 
reduction of iAsV into iAsIII by glutathione as 
reducing agent. We also evaluated the effect 
of methyl group donors. In contrast to methi­
onine, methyl  cobalamin may be an effective 
methyl group donor, resulting in the efficient 
methylation (19%) of iAsV into MMAV and 
MMAIII (Table 2). The methylation efficiency 
increased to 25% upon cosupplementation 
of methylcobalamin and glutathione. We 
attributed this to the increased reduction of 
MMAV into MMAIII by glutathione as reduc­
ing agent. In contrast to the colon digests with 
low levels of iAsV (225 µg/L), no MMMTAV 
was detected in the fecal digests. A probable 
explanation is the difference in experimental 
setup, the difference in microbial community 
composition and activity, or a difference in 
sulfide availability. These observations confirm 
a previous report that addition of cofactors 
may increase As methylation by enteric micro­
organisms, yet it is not a prerequisite for the 
methylation of low levels of As (micrograms 
per liter range) (Hall et al. 1997).
The present study provides evidence 
for the existence of significant presystemic 
As metabolism by human gut microorgan­
isms, but the relevance for the total risk of 
oral As exposure is not yet clear. So far, the 
in vitro approach for assessing the risks from 
oral contaminant exposure mainly involved 
the use of models that focus on gastric and 
intestinal processes. Methylation of As by 
intestinal micro  organisms was thought Arsenic metabolism by human gut microbiota
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to contribute little to the overall methyla­
tion in vivo (Vahter and Gustafsson 1980) 
because iAsV and iAsIII are rapidly absorbed 
in the small intestine (Vahter 1983), espe­
cially when As is ingested in a soluble matrix 
(e.g., drinking water). However, soil­bound 
and/or dietary­bound As may follow a dif­
ferent digestion scenario in the gut, and a 
large fraction may end up in the colon lumen, 
where it is subjected to the resident micro­
bial community. The finding of MMMTAV 
and the highly toxic MMAIII as metabolites 
from human colon micro  organisms indicates 
that presystemic methylation will not lead 
to detoxification. In addition, in vitro stud­
ies with Caco­2 human epithelial colo  rectal 
adenoc  arcinoma cells suggest that the absorp­
tion of methylated arsenicals (DMAV, 10.0%; 
TMAO, 10.9%) is more efficient than that of 
iAsIII (5.8%) and iAsV (1.6%) (Laparra et al. 
2005, 2007). Intestinal absorption of methy­
lated thioarseni  cals should be examined in 
future research. 
Regarding the variability between indi­
viduals regarding presystemic As metabolism, 
we investigated the gut microbiota from only 
one human. Inter  individual variability in gut 
microbial composition is very high; thus, we 
expect gut microbiota from different individ­
uals to display distinct As metabolic profiles. 
Such inter  individual variation in metabolism 
by human gut microbiota was previously 
reported for ingested phyto  estrogens (Bolca 
et al. 2007) and, interestingly, also for the 
metalloid bismuth (Michalke et al. 2008). 
Therefore, variability in gut microbial As 
metabolism should be given the same atten­
tion as the genetic variations that may gov­
ern interindividual differences in As response 
(Hernandez and Marcos 2008).
Conclusion
The present study shows that presystemic 
metabolism of soil­derived As may be rel­
evant in the human body when significant 
amounts of As become available to colon 
micro  organisms. The absorption kinetics 
of methylated arsenicals and thioarsenicals 
across the gut epithelium and their toxicity 
need further elucidation. We propose that 
the metabolic activity of human colon micro­
organisms be incorporated in development 
of new toxico  kinetic models that assess risks 
from oral As exposure. Mikov (1994) nicely 
summarized the importance of gut micro­
biota, stating that gut microbial metabolism 
must be considered an integral part of drug/
xenobiotic metabolism and toxicity studies. 
In this context, knowledge about gut micro­
bial metabolism must also be translated to 
metal(loid) biotransformation. 
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